Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. HUM
HUM logo

HUM Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
174.629
Open
173.000
VWAP
171.79
Vol
1.38M
Mkt Cap
20.52B
Low
169.780
Amount
237.45M
EV/EBITDA(TTM)
6.88
Total Shares
120.05M
EV
29.09B
EV/OCF(TTM)
31.59
P/S(TTM)
0.16
Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.
Show More

Events Timeline

(ET)
2026-03-03
11:50:00
Humana Partners with Multiple Organizations to Improve Heart Health
select
2026-02-12 (ET)
2026-02-12
16:20:00
Dow Jones Falls 669.42 Points, Nasdaq Drops 469.32 Points
select
2026-02-12
12:20:00
Dow Jones Index Falls 1.10% Amid Technology Profit Concerns
select

News

Yahoo Finance
8.5
03-09Yahoo Finance
PinnedHumana Completes $1 Billion Junior Subordinated Notes Offering
  • Bond Offering Size: Humana Inc. has completed a $1 billion fixed-rate junior subordinated notes offering at 6.625%, which will provide the company with approximately $986 million in net proceeds, enhancing its capital structure.
  • Planned Use of Proceeds: The company intends to use the net proceeds from this bond offering for general corporate purposes, including the repayment of existing debt, particularly borrowings under its commercial paper program, thereby optimizing financial leverage and reducing interest expenses.
  • Underwriter Lineup: The bond offering was jointly managed by prominent financial institutions including Goldman Sachs, J.P. Morgan, Mizuho Securities, Truist, and Wells Fargo, reflecting strong market confidence in Humana's debt instruments.
  • Compliance and Forward-Looking Statements: This offering was made pursuant to an effective registration statement with the SEC, and Humana has issued forward-looking statements to alert investors to potential operational risks and uncertainties, ensuring transparency and compliance.
seekingalpha
7.0
03-10seekingalpha
Congressional Investigation Reveals Medicare Overpayment Issues
  • Medicare Overpayment Investigation: The Joint Economic Committee's investigation revealed that alleged overpayments to Medicare Advantage plans resulted in a $13.4 billion increase in Medicare Part B premiums last year, primarily impacting seniors, highlighting potential financial pressures within the Medicare system.
  • Premium Hike Impact: The investigation found that the average Medicare premium for American seniors rose by approximately 10%, equating to over $200 annually, directly affecting beneficiaries of both Medicare Advantage and standard Medicare, indicating a pressing need for policy adjustments.
  • Insurer Rebuttal: America's Health Insurance Plans (AHIP), representing health insurers, denied the investigation's findings, claiming they were based on “fundamentally flawed data and methodology,” illustrating the industry's strong opposition to policy changes and potential conflicts of interest.
  • Market Participant Overview: UnitedHealth (UNH) stands as the largest player in the Medicare Advantage market, followed by Humana (HUM) and others, underscoring the significant role and influence of major insurers in the evolving landscape of Medicare policy.
Newsfilter
8.5
03-09Newsfilter
Humana Completes $1 Billion Junior Subordinated Notes Offering
  • Offering Size: Humana Inc. has completed a $1 billion fixed-rate junior subordinated notes offering at 6.625%, with expected net proceeds of approximately $986 million, which will be used for general corporate purposes including repayment of existing debt, thereby enhancing financial flexibility.
  • Underwriter Lineup: The offering was managed by prominent financial institutions including Goldman Sachs, J.P. Morgan, Mizuho Securities, Truist, and Wells Fargo, reflecting strong market confidence and support for Humana.
  • Compliance and Transparency: The issuance was conducted under an effective shelf registration statement with the SEC, ensuring compliance and transparency, which may attract more investors for future financing activities.
  • Future Outlook: Humana intends to leverage this financing to improve its capital structure, particularly in the highly competitive healthcare sector, thereby strengthening its market position and financial stability to address future challenges and opportunities.
Newsfilter
2.0
03-06Newsfilter
AM Best Assigns Long-Term Credit Rating to Humana
  • Credit Rating Upgrade: AM Best has assigned a 'bbb-' Long-Term Credit Rating to Humana Inc.'s $1 billion, 6.625% fixed-rate junior subordinated notes, with a stable outlook, indicating the company's solid creditworthiness in financing.
  • Financial Leverage Changes: The issuance is expected to slightly increase Humana's financial leverage to approximately 41.8% by year-end 2025, exceeding the long-term target of 40%, but management aims to manage this through equity increases and continued deleveraging.
  • Liquidity Support: Humana's cash flow in 2025 totaled $0.9 billion, a significant drop from $3 billion in 2024, driven by timing impacts and increased receivables, yet the company maintains good liquidity through $1.1 billion in dividends from subsidiaries and $5 billion in credit lines.
  • Profitability Trends: While Humana achieved strong premium growth in 2025, primarily from its Medicare Advantage segment, net income was impacted by increased utilization and changes in reimbursement, with expectations for positive earnings but margin compression throughout 2026.
seekingalpha
8.5
03-06seekingalpha
Humana Prices $1 Billion Junior Subordinated Notes Offering
  • Bond Offering Size: Humana announced a public offering of $1 billion in fixed-rate junior subordinated notes, expected to close on March 9, 2026, which will provide the company with approximately $986 million in net proceeds, enhancing its capital structure.
  • Clear Use of Proceeds: The company intends to utilize the raised funds for general corporate purposes, including the repayment of existing debt, particularly borrowings under its commercial paper program, thereby reducing financial leverage and optimizing capital allocation.
  • Market Reaction Cautious: Despite the funding support from this bond issuance, the market remains skeptical about Humana's future growth, especially in light of the slowdown in Medicare Advantage growth, which could impact investor confidence.
  • Industry Dynamics Impact: While Humana is acquiring Florida-based primary care organization MaxHealth, it faces competitive pressures from UnitedHealth and CVS, which may have long-term implications for its market share and profitability.
NASDAQ.COM
2.0
03-05NASDAQ.COM
HUM Options Contract Analysis and Investment Opportunities
  • Put Option Appeal: The current bid for the $180.00 put option is $10.10, and if an investor sells this contract, they commit to buying the stock at $180.00, effectively lowering their cost basis to $169.90, which is approximately a 1% discount from the current price of $181.36, making it an attractive alternative for potential buyers.
  • Yield Potential Analysis: Should the put option expire worthless, it would yield a 5.61% return on the cash commitment, equating to an annualized yield of 41.00%, referred to as YieldBoost, highlighting the potential profitability of this contract.
  • Call Option Returns: The $185.00 call option has a current bid of $9.80, and if an investor buys HUM shares at $181.36 and sells this call, they could achieve a total return of 7.41% if the stock is called away at expiration, indicating a lucrative strategy.
  • Risk-Reward Balance: Given that the $185.00 strike price represents a 2% premium over the current stock price, the current data suggests a 50% chance of the call option expiring worthless, allowing investors to retain both their shares and the premium collected, thereby enhancing investment security.
Wall Street analysts forecast HUM stock price to rise
19 Analyst Rating
Wall Street analysts forecast HUM stock price to rise
6 Buy
12 Hold
1 Sell
Moderate Buy
Current: 0.000
sliders
Low
231.00
Averages
290.39
High
344.00
Current: 0.000
sliders
Low
231.00
Averages
290.39
High
344.00
Barclays
Equal Weight
downgrade
$245 -> $176
AI Analysis
2026-02-25
Reason
Barclays
Price Target
$245 -> $176
AI Analysis
2026-02-25
downgrade
Equal Weight
Reason
Barclays lowered the firm's price target on Humana to $176 from $245 and keeps an Equal Weight rating on the shares. The firm is 'incrementally cautious" on the company's expectation that Individual Medicare Advantage margins will double.
Wells Fargo
Equal Weight
downgrade
$290 -> $206
2026-02-18
Reason
Wells Fargo
Price Target
$290 -> $206
2026-02-18
downgrade
Equal Weight
Reason
Wells Fargo lowered the firm's price target on Humana to $206 from $290 and keeps an Equal Weight rating on the shares. The firm notes EPS guidance was established at over $9, with key swing factors being underlying margin improvement on retained MA members and underlying profitability of membership growth. Outsized membership growth leaves a wide range outcomes in Wells' view.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for HUM
Unlock Now

Valuation Metrics

The current forward P/E ratio for Humana Inc (HUM.N) is 19.64, compared to its 5-year average forward P/E of 18.61. For a more detailed relative valuation and DCF analysis to assess Humana Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
18.61
Current PE
19.64
Overvalued PE
20.88
Undervalued PE
16.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
11.87
Current EV/EBITDA
11.44
Overvalued EV/EBITDA
13.45
Undervalued EV/EBITDA
10.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.48
Current PS
0.23
Overvalued PS
0.64
Undervalued PS
0.31

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

stock bearish today
Intellectia · 57 candidates
Market Cap: >= 2.00BPrice Change Pct: <= $-3.00Moving Average Relationship: PriceBelowMA20, PriceBelowMA200
Ticker
Name
Market Cap$
top bottom
BMI logo
BMI
Badger Meter Inc
4.89B
CVNA logo
CVNA
Carvana Co
104.69B
APH logo
APH
Amphenol Corp
198.88B
TLK logo
TLK
Telkom Indonesia (Persero) Tbk PT
23.13B
LPL logo
LPL
LG Display Co Ltd
4.36B
VFC logo
VFC
VF Corp
7.85B
stocks bearish for a week
Intellectia · 82 candidates
Price: >= $5.00Moving Average Relationship: PriceBelowMA20Week Price Change Pct: <= $-7.00Month Price Change Pct: <= $-10.00Monthly Average Dollar Volume: >= 800,000
Ticker
Name
Market Cap$
top bottom
VENU logo
VENU
Venu Holding Corp
364.84M
RGNX logo
RGNX
Regenxbio Inc
698.09M
NNNN logo
NNNN
Anbio Biotechnology
2.89B
HUM logo
HUM
Humana Inc
25.28B
CVLT logo
CVLT
Commvault Systems Inc
4.05B
SMX logo
SMX
SMX (Security Matters) PLC
156.97M
find me stock that have found their bottom
Intellectia · 25 candidates
Weekly Average Turnover: >= 1,000,000Rsi 14: <= 70Moving Average Relationship: PriceCrossAboveMA20Support Resistance Relationship: PriceAroundSupport
Ticker
Name
Market Cap$
top bottom
SCHW logo
SCHW
Charles Schwab Corp
180.87B
UBS logo
UBS
UBS Group AG
148.23B
BCS logo
BCS
Barclays PLC
89.27B
ING logo
ING
ING Groep NV
83.26B
NSC logo
NSC
Norfolk Southern Corp
64.87B
MFC logo
MFC
Manulife Financial Corp
62.58B
stocks with wolfe wave buy signals
Intellectia · 43 candidates
Relative Vol: >= 0.800Rsi 14: 40 - 70Moving Average Relationship: PriceAboveMA20Candlestick Pattern: WhiteCandlestickSupport Resistance Relationship: PriceAroundSupport
Ticker
Name
Market Cap$
top bottom
SCHW logo
SCHW
Charles Schwab Corp
180.87B
UBS logo
UBS
UBS Group AG
148.23B
BCS logo
BCS
Barclays PLC
89.27B
ING logo
ING
ING Groep NV
83.26B
NSC logo
NSC
Norfolk Southern Corp
64.87B
MFC logo
MFC
Manulife Financial Corp
62.58B
suche andere Möglichkeiten bzw. Aktien
Intellectia · 25 candidates
Beta: LowRiskAnalyst Action: UpgradeTarget Price Upside Potential: AbovePriceMonth Price Change Pct: >= $5.00Is Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
CVX logo
CVX
Chevron Corp
335.71B
MRK logo
MRK
Merck & Co Inc
275.78B
TMO logo
TMO
Thermo Fisher Scientific Inc
239.06B
BA logo
BA
Boeing Co
190.08B
HON logo
HON
Honeywell International Inc
139.15B
GD logo
GD
General Dynamics Corp
98.53B
show me stocks with a bullish reversal
Intellectia · 131 candidates
Relative Vol: >= 1.20Rsi 14: 30 - 60Moving Average Relationship: PriceCrossAboveMA20Candlestick Pattern: WhiteCandlestickMonth Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
GOOG logo
GOOG
Alphabet Inc
3.96T
LLY logo
LLY
Eli Lilly and Co
1.02T
SCHW logo
SCHW
Charles Schwab Corp
180.87B
BTI logo
BTI
British American Tobacco plc
125.29B
ARM logo
ARM
Arm Holdings PLC
120.87B
COP logo
COP
ConocoPhillips
120.05B

Whales Holding HUM

M
Maple Rock Capital Partners Inc.
Holding
HUM
+28.07%
3M Return
P
Pacific Investment Management Company LLC
Holding
HUM
+16.21%
3M Return
S
Slate Path Capital LP
Holding
HUM
+16.08%
3M Return
C
Crake Asset Management LLP
Holding
HUM
+4.96%
3M Return
A
ARGA Investment Management, LLC
Holding
HUM
+4.09%
3M Return
W
Wolverine Trading, LLC
Holding
HUM
+3.43%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Humana Inc (HUM) stock price today?

The current price of HUM is 170.95 USD — it has decreased -1.54

What is Humana Inc (HUM)'s business?

Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.

What is the price predicton of HUM Stock?

Wall Street analysts forecast HUM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUM is290.39 USD with a low forecast of 231.00 USD and a high forecast of 344.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Humana Inc (HUM)'s revenue for the last quarter?

Humana Inc revenue for the last quarter amounts to 32.52B USD, increased 11.30

What is Humana Inc (HUM)'s earnings per share (EPS) for the last quarter?

Humana Inc. EPS for the last quarter amounts to -6.61 USD, increased 14.96

How many employees does Humana Inc (HUM). have?

Humana Inc (HUM) has 67060 emplpoyees as of March 12 2026.

What is Humana Inc (HUM) market cap?

Today HUM has the market capitalization of 20.52B USD.